11 October 2022 - Application is based on randomised, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency.

Pharming Group announces that it has submitted a marketing authorisation application to the EMA for leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, as a treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency, in adults and adolescents 12 years or older.

Read Pharming press release